RBC Capital raised the firm’s price target on BeOne Medicines (ONC) to $408 from $395 and keeps an Outperform rating on the shares. The Ziihera phase III HORIZON-GEA update clears the way for a potential 1L approval in combination with Tevimbra and chemotherapy and adds incremental upside to shares, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- BeOne Medicines: Buy Rating Driven by Robust Global Vision and Strong Financial Performance
- BeOne Medicines price target raised to $420 from $398 at Jefferies
- Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
- Zymeworks’ Ziihera shows efficacy in Phase 3 adenocarcinoma trial